As of 2025-07-06, the EV/EBITDA ratio of Transgene Biotek Ltd (526139.BO) is -150.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 526139.BO's latest enterprise value is 509.84 mil INR. 526139.BO's TTM EBITDA according to its financial statements is -3.40 mil INR. Dividing these 2 quantities gives us the above 526139.BO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 3.8x - 8.5x | 4.8x |
| Forward P/E multiples | 11.8x - 16.5x | 14.8x |
| Fair Price | (2.41) - (2.26) | (2.32) |
| Upside | -149.7% - -146.6% | -147.8% |
| Date | EV/EBITDA |
| 2025-02-25 | -136.22 |
| 2025-02-21 | -135.32 |
| 2025-02-20 | -136.66 |
| 2025-02-19 | -136.66 |
| 2025-02-18 | -131.09 |
| 2025-02-17 | -135.10 |
| 2025-02-14 | -140.01 |
| 2025-02-13 | -139.78 |
| 2025-02-12 | -141.34 |
| 2025-02-11 | -142.24 |
| 2025-02-10 | -143.13 |
| 2025-02-07 | -143.57 |
| 2025-02-06 | -142.91 |
| 2025-02-05 | -142.46 |
| 2025-02-04 | -142.46 |
| 2025-02-03 | -143.80 |
| 2025-02-01 | -145.58 |
| 2025-01-31 | -144.47 |
| 2025-01-30 | -148.26 |
| 2025-01-29 | -146.47 |
| 2025-01-28 | -143.13 |
| 2025-01-27 | -142.01 |
| 2025-01-24 | -142.24 |
| 2025-01-23 | -147.59 |
| 2025-01-22 | -146.92 |
| 2025-01-21 | -148.93 |
| 2025-01-20 | -148.48 |
| 2025-01-17 | -152.72 |
| 2025-01-16 | -147.59 |
| 2025-01-15 | -142.68 |
| 2025-01-14 | -138.00 |
| 2025-01-13 | -137.11 |
| 2025-01-10 | -133.32 |
| 2025-01-09 | -138.00 |
| 2025-01-08 | -142.91 |
| 2025-01-07 | -148.03 |
| 2025-01-06 | -153.61 |
| 2025-01-03 | -159.41 |
| 2025-01-02 | -165.43 |
| 2025-01-01 | -179.03 |
| 2024-12-31 | -194.19 |
| 2024-12-30 | -203.56 |
| 2024-12-27 | -210.25 |
| 2024-12-26 | -204.90 |
| 2024-12-24 | -199.77 |
| 2024-12-23 | -202.44 |
| 2024-12-20 | -208.46 |
| 2024-12-19 | -208.69 |
| 2024-12-18 | -206.90 |
| 2024-12-17 | -206.68 |